Do analysts recommend PULM or NKGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PULM or NKGN more profitable?

NKGen Biotech's return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -125.65% -95.19% NKGen Biotech N/A N/A -479.36%

Do analysts rate SNOA or NKGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer NKGN or EOCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NKGN or EOCN?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.68 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A

Is NKGN or EOCN more profitable?

NKGen Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Galmed Pharmaceuticals N/A -73.68% -60.88%

Do analysts recommend NKGN or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, NKGN or NCNA?

NuCana is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.68 N/A NuCana N/A N/A -$38.71M -$3.81 N/A

Is NKGN or NCNA more profitable?

NKGen Biotech's return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% NuCana N/A -41.90% -33.69%

Do analysts recommend NKGN or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NKGN or INM more profitable?

NKGen Biotech's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% InMed Pharmaceuticals N/A -156.08% -123.90%

NKGen Biotech (NKGN) Competitors

$0.01 0.00 (0.00%)

As of 10/13/2026

Compare

NKGN vs. PULM, SNOA, GLMD, NCNA, and INM

Should you buy NKGen Biotech stock or one of its competitors? NKGen Biotech's main competitors and comparable companies include Pulmatrix (PULM), Sonoma Pharmaceuticals (SNOA), Galmed Pharmaceuticals (GLMD), NuCana (NCNA), and InMed Pharmaceuticals (INM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NKGen Biotech compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Pulmatrix has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

NKGen Biotech's return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-125.65%	-95.19%
NKGen Biotech	N/A	N/A	-479.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Pulmatrix had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Pulmatrix and 0 mentions for NKGen Biotech. Pulmatrix's average media sentiment score of 1.23 beat NKGen Biotech's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmatrix	Positive
NKGen Biotech	Neutral

Pulmatrix has higher revenue and earnings than NKGen Biotech. Pulmatrix is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.64	-$5.16M	-$1.10	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

Summary

Pulmatrix beats NKGen Biotech on 8 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Sonoma Pharmaceuticals has higher revenue and earnings than NKGen Biotech. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.29	-$3.17M	-$1.22	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

Sonoma Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Sonoma Pharmaceuticals and 0 mentions for NKGen Biotech. Sonoma Pharmaceuticals' average media sentiment score of 1.82 beat NKGen Biotech's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Very Positive
NKGen Biotech	Neutral

NKGen Biotech has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. NKGen Biotech's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
NKGen Biotech	N/A	N/A	-479.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Sonoma Pharmaceuticals beats NKGen Biotech on 8 of the 13 factors compared between the two stocks.

How does NKGen Biotech compare to Galmed Pharmaceuticals?

NKGen Biotech (NYSE:NKGN) and Galmed Pharmaceuticals (NASDAQ:EOCN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for NKGen Biotech. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat NKGen Biotech's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
Galmed Pharmaceuticals	Positive

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

NKGen Biotech has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

NKGen Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Galmed Pharmaceuticals beats NKGen Biotech on 6 of the 10 factors compared between the two stocks.

How does NKGen Biotech compare to NuCana?

NKGen Biotech (NYSE:NKGN) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NuCana is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

In the previous week, NuCana had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for NuCana and 0 mentions for NKGen Biotech. NuCana's average media sentiment score of 1.82 beat NKGen Biotech's score of 0.00 indicating that NuCana is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
NuCana	Very Positive

NKGen Biotech has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, NuCana has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NKGen Biotech's return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NuCana	N/A	-41.90%	-33.69%

Summary

NuCana beats NKGen Biotech on 7 of the 10 factors compared between the two stocks.

How does NKGen Biotech compare to InMed Pharmaceuticals?

NKGen Biotech (NYSE:NKGN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, InMed Pharmaceuticals had 9 more articles in the media than NKGen Biotech. MarketBeat recorded 9 mentions for InMed Pharmaceuticals and 0 mentions for NKGen Biotech. InMed Pharmaceuticals' average media sentiment score of 0.57 beat NKGen Biotech's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
InMed Pharmaceuticals	Positive

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InMed Pharmaceuticals has higher revenue and earnings than NKGen Biotech. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
InMed Pharmaceuticals	$4.94M	0.89	-$12.56M	-$1.64	N/A

NKGen Biotech's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

NKGen Biotech has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

InMed Pharmaceuticals beats NKGen Biotech on 8 of the 12 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKGN vs. The Competition

Export

Metric	NKGen Biotech	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.45M	$12.35B	$7.25B	$22.90B
Dividend Yield	N/A	2.63%	2.52%	3.72%
P/E Ratio	0.00	807.81	275.44	28.17
Price / Sales	N/A	748.69	562.05	20.91
Price / Cash	N/A	86.65	77.16	37.05
Price / Book	0.00	9.26	10.64	4.67
Net Income	-$82.94M	$2.83B	$3.49B	$1.07B
7 Day Performance	N/A	-3.62%	-3.21%	-0.67%
1 Month Performance	N/A	-7.66%	-7.65%	-4.30%
1 Year Performance	N/A	-5.44%	2.92%	5.52%

NKGen Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKGN NKGen Biotech	N/A	$0.01 flat	N/A	N/A	$1.45M	N/A	N/A	26
PULM Pulmatrix	1.0293 of 5 stars	$1.46 -4.4%	N/A	-71.8%	$5.58M	$7.81M	N/A	2	Gap Down
SNOA Sonoma Pharmaceuticals	0.7915 of 5 stars	$1.23 +6.0%	N/A	-71.0%	$5.55M	$19.53M	N/A	260
GLMD Galmed Pharmaceuticals	N/A	$4.59 -0.9%	N/A	N/A	$4.78M	N/A	N/A	20	Gap Down High Trading Volume
NCNA NuCana	1.3278 of 5 stars	$1.10 -2.7%	N/A	-81.8%	$4.70M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NKGen Biotech (NKGN) Competitors

NKGN vs. PULM, SNOA, GLMD, NCNA, and INM

How does NKGen Biotech compare to Pulmatrix?

Summary

How does NKGen Biotech compare to Sonoma Pharmaceuticals?

Summary

How does NKGen Biotech compare to Galmed Pharmaceuticals?

Summary

How does NKGen Biotech compare to NuCana?

Summary

How does NKGen Biotech compare to InMed Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NKGen Biotech (NKGN) Competitors

NKGN vs. PULM, SNOA, GLMD, NCNA, and INM

How does NKGen Biotech compare to Pulmatrix?

Which has more volatility and risk, PULM or NKGN?

Is PULM or NKGN more profitable?

Do analysts recommend PULM or NKGN?

Do institutionals & insiders believe in PULM or NKGN?

Does the media refer more to PULM or NKGN?

Which has higher valuation & earnings, PULM or NKGN?

Summary

How does NKGen Biotech compare to Sonoma Pharmaceuticals?

Which has preferable valuation and earnings, SNOA or NKGN?

Which has more risk and volatility, SNOA or NKGN?

Do insiders and institutionals have more ownership in SNOA or NKGN?

Does the media favor SNOA or NKGN?

Is SNOA or NKGN more profitable?

Do analysts rate SNOA or NKGN?

Summary

How does NKGen Biotech compare to Galmed Pharmaceuticals?

Do analysts prefer NKGN or EOCN?

Does the media refer more to NKGN or EOCN?

Which has better valuation and earnings, NKGN or EOCN?

Which has more volatility & risk, NKGN or EOCN?

Is NKGN or EOCN more profitable?

Do institutionals & insiders have more ownership in NKGN or EOCN?

Summary

How does NKGen Biotech compare to NuCana?

Do insiders & institutionals hold more shares of NKGN or NCNA?

Which has preferable earnings and valuation, NKGN or NCNA?

Does the media prefer NKGN or NCNA?

Which has more risk & volatility, NKGN or NCNA?

Do analysts recommend NKGN or NCNA?

Is NKGN or NCNA more profitable?

Summary

How does NKGen Biotech compare to InMed Pharmaceuticals?

Does the media prefer NKGN or INM?

Do insiders and institutionals hold more shares of NKGN or INM?

Which has stronger valuation and earnings, NKGN or INM?

Is NKGN or INM more profitable?

Which has more risk and volatility, NKGN or INM?

Do analysts recommend NKGN or INM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools